Log in

Relevant bibliographies by topics / Antiangiogenic treatment / Journal articles

To see the other types of publications on this topic, follow the link: Antiangiogenic treatment.

Journal articles on the topic 'Antiangiogenic treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 27 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antiangiogenic treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Alfred, J. "Antiangiogenic cancer treatment." Trends in Genetics 14, no. 3 (1998): 91. http://dx.doi.org/10.1016/s0168-9525(98)01435-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zhou, Jianhua, Wei Zheng, Longhui Cao, Min Liu, Feng Han, and Anhua Li. "Antiangiogenic Tumor Treatment." Academic Radiology 17, no. 5 (2010): 646–51. http://dx.doi.org/10.1016/j.acra.2010.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Pimolbutr, Kununya, Stephen Porter, and Stefano Fedele. "Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature." BioMed Research International 2018 (2018): 1–14. http://dx.doi.org/10.1155/2018/8071579.

Full text

Abstract:

Objectives. To review the available literature on medication-related osteonecrosis of the jaw (MRONJ) associated with antiangiogenics in antiresorptive-naïve individuals. Methods. A literature search was performed using MEDLINE via PubMed, EMBASE, and Web of Science in December 2017. Results. We identified reports describing a total of 35 antiresorptive drugs-naïve patients who developed antiangiogenic-related MRONJ. The mean age of these patients was 59.06 years and the F : M ratio was 4 : 5. The most common underlying disease was metastatic renal cell cancer. Pain to the mandible was the mos

APA, Harvard, Vancouver, ISO, and other styles

4

Rahman, Md Ataur, and Meser M. Ali. "Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma." Cancers 16, no. 17 (2024): 2975. http://dx.doi.org/10.3390/cancers16172975.

Full text

Abstract:

Malignant gliomas present great difficulties in treatment, with little change over the past 30 years in the median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing the formation of new vasculature (antiangiogenic treatments) or destroying formed tumor vasculature (vascular disrupting agents) show promise. This study summarizes the existing knowledge regarding the processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses the activation of r

APA, Harvard, Vancouver, ISO, and other styles

5

Shinozaki, Eiji, Akitaka Makiyama, Yoshinori Kagawa, et al. "Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database." PLOS ONE 16, no. 2 (2021): e0246160. http://dx.doi.org/10.1371/journal.pone.0246160.

Full text

Abstract:

The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan. This retrospective observational study was conducted using a Japanese hospital-based administrative database. Patients were enrolled if they started adjuvant therapy (and presumably experienced early recurrence) or first-line treatment for

APA, Harvard, Vancouver, ISO, and other styles

6

Aguiar, Pedro, Tiago Costa de Pádua, Carmelia Maria Noia Barreto, and Auro del Giglio. "Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges." Clinical Medicine Insights: Urology 11 (January 1, 2018): 117956111876575. http://dx.doi.org/10.1177/1179561118765758.

Full text

Abstract:

Recently, the development of antiangiogenic drugs has changed the therapy for metastatic renal cell carcinoma (RCC). As a result, the survival of individuals with advanced RCC has more than doubled. The median overall survival improved from 12 months during the cytokines era to near 30 months with antiangiogenic drugs. In this decade, the advent of immune checkpoint inhibitors showed enthusiastic results and is the new standard of care for patients with metastatic RCC previously treated with antiangiogenic drugs. The combination of immune checkpoint inhibitors plus antiangiogenic drugs may hav

APA, Harvard, Vancouver, ISO, and other styles

7

López-Letayf, Sonia, Oscar Vivanco-Rojas, Valentina Londoño-Angarita, Fátima Sofía Magaña-Guerrero, Beatriz Buentello-Volante, and Yonathan Grafias. "Intravitreal Antiangiogenic Treatment for Diabetic Retinopathy: A Mexican Real-Life Scenario Experience." Life 14, no. 8 (2024): 976. http://dx.doi.org/10.3390/life14080976.

Full text

Abstract:

The objective of this study was to analyze the effectiveness of two intravitreal antiangiogenic drugs, ranibizumab and aflibercept, in a Mexican population over a period of 5 years, evaluating the improvement in visual acuity (VA) and central retinal thickness (CRT) in a real-world scenario. This is a retrospective study with subjects diagnosed with diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR), and diabetic macular edema (DME) receiving intravitreal injections of ranibizumab and/or aflibercept. In this study, we analyzed 588 eyes of 294 patients who received intravitreal

APA, Harvard, Vancouver, ISO, and other styles

8

Bartsch, Rupert, Anna S. Berghoff, Matthias Preusser, Guenther G. Steger, and Christoph C. Zielinski. "Antiangiogenic treatment approaches in breast cancer." Breast Cancer Management 2, no. 5 (2013): 397–406. http://dx.doi.org/10.2217/bmt.13.37.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Riklin, Christian, Katharina Seystahl, Silvia Hofer, Caroline Happold, Ralph Winterhalder, and Michael Weller. "Antiangiogenic Treatment for Multiple CNS Hemangioblastomas." Onkologie 35, no. 7-8 (2012): 443–45. http://dx.doi.org/10.1159/000341075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Galsky, Matthew D. "Antiangiogenic treatment in metastatic urothelial cancer." Lancet Oncology 13, no. 8 (2012): 748–49. http://dx.doi.org/10.1016/s1470-2045(12)70319-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Voutouri, Chrysovalantis, Nathaniel D. Kirkpatrick, Euiheon Chung, et al. "Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies." Proceedings of the National Academy of Sciences 116, no. 7 (2019): 2662–71. http://dx.doi.org/10.1073/pnas.1818322116.

Full text

Abstract:

Cooption of the host vasculature is a strategy that some cancers use to sustain tumor progression without—or before—angiogenesis or in response to antiangiogenic therapy. Facilitated by certain growth factors, cooption can mediate tumor infiltration and confer resistance to antiangiogenic drugs. Unfortunately, this mode of tumor progression is difficult to target because the underlying mechanisms are not fully understood. Here, we analyzed the dynamics of vessel cooption during tumor progression and in response to antiangiogenic treatment in gliomas and brain metastases. We followed tumor evol

APA, Harvard, Vancouver, ISO, and other styles

12

Jin, Chengwen, Mingyuan Yuan, Hualei Bu, and Chengjuan Jin. "Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy." Journal of Oncology 2022 (April 12, 2022): 1–15. http://dx.doi.org/10.1155/2022/4880355.

Full text

Abstract:

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved targeted agent in ovarian cancer. Anti-angiogenic agents mainly include agents target VEGF/VEGFR pathway, such as bevacizumab and agents target receptor tyrosine kinase, and non-VEGF/VEGFR targets of angiogenesis. Antiangiogenic agents demonstrate certain effects in ovarian cancer treatment either as monotherapy or combined with chemotherapy. Unfortunately, antiangiogenic agents, such as bevacizumab, integrated into t

APA, Harvard, Vancouver, ISO, and other styles

13

Teoh, Deanna, and Angeles Alvarez Secord. "Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer." International Journal of Gynecologic Cancer 22, no. 3 (2012): 348–59. http://dx.doi.org/10.1097/igc.0b013e31823c6efd.

Full text

Abstract:

ObjectiveThe purpose of this review was to provide an overview of angiogenesis, including the rationale for targeting angiogenesis as a treatment strategy for epithelial ovarian cancer (EOC) and to discuss available clinical trial data with antiangiogenic agents in EOC, with a focus on combinations with chemotherapy.MethodsThis was a literature review of clinical studies evaluating select antiangiogenic agents in combination with traditional cytotoxic chemotherapy for the treatment of EOC.ResultsSeveral therapies that target angiogenesis-specific pathways are undergoing clinical development fo

APA, Harvard, Vancouver, ISO, and other styles

14

Leong, Alessandra, and Minah Kim. "The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer." International Journal of Molecular Sciences 21, no. 22 (2020): 8689. http://dx.doi.org/10.3390/ijms21228689.

Full text

Abstract:

Despite significant advances made in cancer treatment, the development of therapeutic resistance to anticancer drugs represents a major clinical problem that limits treatment efficacy for cancer patients. Herein, we focus on the response and resistance to current antiangiogenic drugs and immunotherapies and describe potential strategies for improved treatment outcomes. Antiangiogenic treatments that mainly target vascular endothelial growth factor (VEGF) signaling have shown efficacy in many types of cancer. However, drug resistance, characterized by disease recurrence, has limited therapeutic

APA, Harvard, Vancouver, ISO, and other styles

15

Hofheinz, R. D., U. Ronellenfitsch, S. Kubicka, A. Falcone, I. Burkholder, and U. T. Hacker. "Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials." Gastroenterology Research and Practice 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/9189483.

Full text

Abstract:

Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis.Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF

APA, Harvard, Vancouver, ISO, and other styles

16

Cidon, E. Una, P. Alonso, and B. Masters. "Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where are We Now and What should be Next?" Clinical Medicine Insights: Oncology 10s1 (January 2016): CMO.S34542. http://dx.doi.org/10.4137/cmo.s34542.

Full text

Abstract:

Despite advances in the treatment of colorectal cancer (CRC), it remains the second most common cause of cancer-related death in the Western world. Angiogenesis is a complex process that involves the formation of new blood vessels from preexisting vessels. It is essential for promoting cancer survival, growth, and dissemination. The inhibition of angiogenesis has been shown to prevent tumor progression experimentally, and several chemotherapeutic targets of tumor angiogenesis have been identified. These include anti-vascular endothelial growth factor (VEGF) treatments, such as bevacizumab (a V

APA, Harvard, Vancouver, ISO, and other styles

17

Tempaku, Akira. "A case of perforator area infarction during maintenance chemotherapy for insular glioma with bevacizumab." Case Reports International 14, no. 2 (2025): 1–4. https://doi.org/10.5348/100133z06at2025cr.

Full text

Abstract:

Introduction: Glioblastoma multiforme is one of the most malignant central nervous system neoplasms. Maintaining good daily living activities during the tumor progression-free survival period is desirable. Neurological dysfunctions resulting from surgical treatment-related deficiencies or ischemic stroke during the established treatment protocol should be avoided. Case Report: A 66-year-old woman was diagnosed with glioblastoma multiforme in the right insula. She underwent chemotherapy and radiotherapy following surgical resection. Following the initial standard treatment, she received mainten

APA, Harvard, Vancouver, ISO, and other styles

18

Wilczyńska, U., A. Kucharska, J. Szary, and S. Szala. "Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer." Acta Biochimica Polonica 48, no. 4 (2001): 1077–84. http://dx.doi.org/10.18388/abp.2001_3868.

Full text

Abstract:

We investigated the feasibility of a novel therapeutic approach to treat neoplastic diseases in mice. This novel strategy consists in delivering a protein (angiostatin) with strong antiangiogenic properties, followed by administration of the interleukin 12 gene that is strongly immunomodulatory and has also some antiangiogenic effects. When angiostatin-mediated antiangiogenic therapy was used in combination with intratumor delivery of the IL-12 gene (a strategy much safer than IL-12 protein administration), this produced a synergistic therapeutic effect.

APA, Harvard, Vancouver, ISO, and other styles

19

Cea, Valentina, Carlo Sala, and Chiara Verpelli. "Antiangiogenic Therapy for Glioma." Journal of Signal Transduction 2012 (July 8, 2012): 1–15. http://dx.doi.org/10.1155/2012/483040.

Full text

Abstract:

Currently, antiangiogenic agents are routinely used for the treatment of patients with glioma. However, despite advances in pharmacological and surgical therapy, glioma remains an incurable disease. Indeed, the formation of an abnormal tumor vasculature and the invasion of glioma cells along neuronal tracts are proposed to comprise the major factors that are attributed to the therapeutic resistance of these tumors. The development of curative therapeutic modalities for the treatment of glioma requires further investigation of the molecular mechanisms regulating angiogenesis and invasion. In th

APA, Harvard, Vancouver, ISO, and other styles

20

Montagnani, Francesco, Greta Di Leonardo, Mariasimona Pino, Simona Perboni, Angela Ribecco, and Luisa Fioretto. "Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review." Journal of Translational Internal Medicine 5, no. 1 (2017): 18–26. http://dx.doi.org/10.1515/jtim-2017-0005.

Full text

Abstract:

Abstract Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive literature search was conducted. Hazard ratios (HR) for progression (PFS) and death (OS) were extracted. An inverse-variance meta-analysis model was implemented. 6 randomized controlled trials were retrieved, including 3407 patients,

APA, Harvard, Vancouver, ISO, and other styles

21

de Bernardi, Axel, Armelle Dufresne, Florence Mishellany, Jean-Yves Blay, Isabelle Ray-Coquard, and Mehdi Brahmi. "Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond." Cancers 14, no. 4 (2022): 1064. http://dx.doi.org/10.3390/cancers14041064.

Full text

Abstract:

SFT is an ultrarare mesenchymal ubiquitous tumor, with an incidence rate <1 case/million people/year. The fifth WHO classification published in April 2020 subdivided SFT into three categories: benign (locally aggressive), NOS (rarely metastasizing), and malignant. Recurrence can occur in up to 10–40% of localized SFTs, and several risk stratification models have been proposed to predict the individual risk of metastatic relapse. The Demicco model is the most widely used and is based on age at presentation, tumor size, and mitotic count. Total en bloc resection is the standard treatment of p

APA, Harvard, Vancouver, ISO, and other styles

22

Morotti, Matteo, and Simone Ferrero. "Antiangiogenic Drugs in the Treatment of Endometriosis." Reproductive Sciences 20, no. 3 (2012): NP1—NP2. http://dx.doi.org/10.1177/1933719112468955.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Vincenzi, B., D. Santini, L. Rocci, and G. Tonini. "Bisphosphonates: new antiangiogenic molecules in cancer treatment?" Annals of Oncology 14, no. 5 (2003): 806. http://dx.doi.org/10.1093/annonc/mdg194.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gerstner, Elizabeth R., Dan G. Duda, Emmanuelle di Tomaso, Greg Sorensen, Rakesh K. Jain, and Tracy T. Batchelor. "Antiangiogenic agents for the treatment of glioblastoma." Expert Opinion on Investigational Drugs 16, no. 12 (2007): 1895–908. http://dx.doi.org/10.1517/13543784.16.12.1895.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Hlatky, L. "SP-0105: Current development in antiangiogenic treatment." Radiotherapy and Oncology 111 (2014): S43. http://dx.doi.org/10.1016/s0167-8140(15)30210-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chinot, Oliver L., and David A. Reardon. "The future of antiangiogenic treatment in glioblastoma." Current Opinion in Neurology 27, no. 6 (2014): 675–82. http://dx.doi.org/10.1097/wco.0000000000000142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Chi, Andrew S., Andrew D. Norden, and Patrick Y. Wen. "Antiangiogenic strategies for treatment of malignant gliomas." Neurotherapeutics 6, no. 3 (2009): 513–26. http://dx.doi.org/10.1016/j.nurt.2009.04.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Marra, Diego E., Harley A. Haynes, and Vincent W. Li. "Antiangiogenic treatment of pyogenic granuloma with imiquimod." Journal of the American Academy of Dermatology 50, no. 3 (2004): P57. http://dx.doi.org/10.1016/j.jaad.2003.10.219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Nikolaou, Vasiliki, Alexander Stratigos, Dimitrios Bafaloukos, and Andreas Katsambas. "Antiangiogenic and antiapoptotic treatment in advanced melanoma." Clinics in Dermatology 31, no. 3 (2013): 257–63. http://dx.doi.org/10.1016/j.clindermatol.2012.08.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chamberlain, Marc C. "Antiangiogenic blockage: a new treatment for glioblastoma." Expert Opinion on Biological Therapy 8, no. 10 (2008): 1449–53. http://dx.doi.org/10.1517/14712598.8.10.1449.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Morère, J. F., J. M. Brechot, and R. Etessami. "Angiogenesis and antiangiogenic treatment in lung cancer." Targeted Oncology 1, no. 4 (2006): 215–19. http://dx.doi.org/10.1007/s11523-006-0031-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Recouvreux, M. Victoria, M. Andrea Camilletti, Daniel B. Rifkin, Damasia Becu-Villalobos та Graciela Díaz-Torga. "Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 Inhibit Prolactinoma Growth and Recover Active Pituitary Transforming Growth Factor-β1 (TGF-β1)". Endocrinology 153, № 8 (2012): 3861–71. http://dx.doi.org/10.1210/en.2012-1007.

Full text

Abstract:

Prolactinomas are the most prevalent type of secreting pituitary tumors in humans and generally respond well to a medical therapy with dopamine agonists. However, for patients exhibiting resistance to dopaminergic drugs, alternative treatments are desired. Antiangiogenic strategies might represent a potential therapy for these tumors. Thrombospondin 1 (TSP-1) is a large multifunctional glycoprotein involved in multiple biological processes including angiogenesis, apoptosis, and activation of TGF-β1. Because tumors that overexpress TSP-1 grow more slowly, have fewer metastases, and have decreas

APA, Harvard, Vancouver, ISO, and other styles

33

Argyri, Katerina D., Dimitra D. Dionysiou, Fay D. Misichroni, and Georgios S. Stamatakos. "Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data." Biology Direct 11, no. 1 (2016): 12. https://doi.org/10.1186/s13062-016-0114-9.

Full text

Abstract:

<strong>Background: </strong>Antiangiogenic agents have been recently added to the oncological armamentarium with bevacizumab probably being the most popular representative in current clinical practice. The elucidation of the mode of action of these agents is a prerequisite for personalized prediction of antiangiogenic treatment response and selection of patients who may benefit from this kind of therapy. To this end, having used as a basis a preexisting continuous vascular tumour growth model which addresses the targeted nature of antiangiogenic treatment, we present a paper characterized by

APA, Harvard, Vancouver, ISO, and other styles

34

Mendoza-Torreblanca, Julieta Griselda, Noemi Cárdenas-Rodríguez, Jazmín Carro-Rodríguez, et al. "Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis." International Journal of Molecular Sciences 24, no. 12 (2023): 10199. http://dx.doi.org/10.3390/ijms241210199.

Full text

Abstract:

Dopamine (DA) and dopamine agonists (DA-Ag) have shown antiangiogenic potential through the vascular endothelial growth factor (VEGF) pathway. They inhibit VEGF and VEGF receptor 2 (VEGFR 2) functions through the dopamine receptor D2 (D2R), preventing important angiogenesis-related processes such as proliferation, migration, and vascular permeability. However, few studies have demonstrated the antiangiogenic mechanism and efficacy of DA and DA-Ag in diseases such as cancer, endometriosis, and osteoarthritis (OA). Therefore, the objective of this review was to describe the mechanisms of the ant

APA, Harvard, Vancouver, ISO, and other styles

35

Sarkar, Chandrani, Sandeep Goswami, Sujit Basu, and Debanjan Chakroborty. "Angiogenesis Inhibition in Prostate Cancer: An Update." Cancers 12, no. 9 (2020): 2382. http://dx.doi.org/10.3390/cancers12092382.

Full text

Abstract:

Prostate cancer (PCa), like all other solid tumors, relies on angiogenesis for growth, progression, and the dissemination of tumor cells to other parts of the body. Despite data from in vitro and in vivo preclinical studies, as well as human specimen studies indicating the crucial role played by angiogenesis in PCa, angiogenesis inhibition in clinical settings has not shown significant benefits to patients, thus challenging the inclusion and usefulness of antiangiogenic agents for the treatment of PCa. However, one of the apparent reasons why these antiangiogenic agents failed to meet expectat

APA, Harvard, Vancouver, ISO, and other styles

36

Yanwei, Li, Yang Yinli, and Zhanyu Pan. "Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells." Evidence-Based Complementary and Alternative Medicine 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/5291517.

Full text

Abstract:

Antiangiogenic therapy is vital in nasopharyngeal carcinoma (NPC) treatment. NPC01 has already been successfully used in treating patients with NPC in clinical practice and exerted an excellent antiangiogenetic effect. However, the potential molecular mechanism underlying the antitumor effect of NPC01 has not been well explored. The present study demonstrated that NPC01 could significantly inhibit cell proliferation and induce cell apoptosis in a dose-dependent manner in human NPC cell lines. Furthermore, NPC01 exerted antiproliferative and antiangiogenic effects in NPC xenograft mice. Moreove

APA, Harvard, Vancouver, ISO, and other styles

37

Baltes-Breitwisch, Michelle M., Robin A. Artac, Rebecca C. Bott, et al. "Neutralization of vascular endothelial growth factor antiangiogenic isoforms or administration of proangiogenic isoforms stimulates vascular development in the rat testis." REPRODUCTION 140, no. 2 (2010): 319–29. http://dx.doi.org/10.1530/rep-09-0456.

Full text

Abstract:

Vascular endothelial growth factor A (VEGFA) plays a role in both angiogenesis and seminiferous cord formation, and alternative splicing of theVegfagene produces both proangiogenic isoforms and antiangiogenic isoforms (B-isoforms). The objectives of this study were to evaluate the expression of pro- and antiangiogenic isoforms during testis development and to determine the role of VEGFA isoforms in testis morphogenesis. Quantitative RT-PCR determined thatVegfa_165bmRNA was most abundant between embryonic days 13.5 and 16 (E13.5 and 16;P<0.05). Compared with ovarian mRNA levels,Vegfa_120was

APA, Harvard, Vancouver, ISO, and other styles

38

Nery de Albuquerque Rego, Gabriel, Arielly da Hora Alves, Mariana Penteado Nucci, Javier Bustamante Mamani, Fernando Anselmo de Oliveira, and Lionel Fernel Gamarra. "Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations." International Journal of Molecular Sciences 21, no. 12 (2020): 4490. http://dx.doi.org/10.3390/ijms21124490.

Full text

Abstract:

Glioblastoma (GBM) is the most aggressive tumor type whose resistance to conventional treatment is mediated, in part, by the angiogenic process. New treatments involving the application of nanoformulations composed of encapsulated drugs coupled to peptide motifs that direct drugs to specific targets triggered in angiogenesis have been developed to reach and modulate different phases of this process. We performed a systematic review with the search criterion (Glioblastoma OR Glioma) AND (Therapy OR Therapeutic) AND (Nanoparticle) AND (Antiangiogenic OR Angiogenesis OR Anti-angiogenic) in Pubmed

APA, Harvard, Vancouver, ISO, and other styles

39

Jimenez, Camilo, Sasan Fazeli, and Alejandro Román-Gonzalez. "Antiangiogenic therapies for pheochromocytoma and paraganglioma." Endocrine-Related Cancer 27, no. 7 (2020): R239—R254. http://dx.doi.org/10.1530/erc-20-0043.

Full text

Abstract:

Metastatic pheochromocytomas and paragangliomas are rare, highly vascular tumors that spread primarily to the lymph nodes, skeletal tissue, lungs, and liver. Tumor morbidity is related to their size, location, hormonal activity, vascular nature, and rate of progression. Systemic therapies for this indication are limited. Only high-specific-activity iodine-131 metaiodobenzylguanidine is approved in the Unites States for treatment of these patients, and not all patients are candidates for this radiopharmaceutical. Antiangiogenic medications are currently being evaluated in prospective clinical t

APA, Harvard, Vancouver, ISO, and other styles

40

Riechelmann, Rachel, and Axel Grothey. "Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies." Therapeutic Advances in Medical Oncology 9, no. 2 (2016): 106–26. http://dx.doi.org/10.1177/1758834016676703.

Full text

Abstract:

Even though significant improvements in the treatment of colorectal cancer (CRC) have been made in recent years, survival rates for metastatic colorectal cancer (mCRC) are poor. Effective treatment options for metastatic colorectal cancer remain limited, and new therapeutic strategies are desperately needed. Several tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) that target angiogenesis, a critical process for facilitating tumor cell growth, invasion, and metastasis, are either approved or in clinical development for the treatment of mCRC. Many of these agents have shown ef

APA, Harvard, Vancouver, ISO, and other styles

41

Jiménez-Valerio, Gabriela, and Oriol Casanovas. "Antiangiogenic resistance: novel angiogenesis axes uncovered by antiangiogenic therapies research - pubmed." Current drug targets 17, no. 15 (2016): 1728–34. https://doi.org/10.2174/1389450117666160301101425.

Full text

Abstract:

The mechanisms of tumor growth and progression involve the activation of different processes such as neovascularization and angiogenesis. These processes involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects tumor growth and proliferation in patients with different types of cancer. Nevertheless, tumoral cells and stromal components are responsible for the resistance to antiangiogenic therapies. The majority of tumors respond to this type of therapy; however, some tumors may be indifferent to antiangiogenic therapies (intrinsic resistance) and other tumors become resis

APA, Harvard, Vancouver, ISO, and other styles

42

Tejada, Miguel Á., Ana I. Santos-Llamas, María José Fernández-Ramírez, Juan J. Tarín, Antonio Cano, and Raúl Gómez. "A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment." Biomedicines 9, no. 3 (2021): 269. http://dx.doi.org/10.3390/biomedicines9030269.

Full text

Abstract:

Dopamine receptor 2 agonists (D2-ags) have been shown to reduce the size of tumors by targeting aberrant angiogenesis in pathological tissue. Because of this, the use of a D2-ag was inferred for endometriosis treatment. When assayed in mouse models however, D2-ags have been shown to cause a shift of the immature vessels towards a more mature phenotype but not a significant reduction in the amount of vascularization and size of lesions. These has raised concerns on whether the antiangiogenic effects of these compounds confer a therapeutic value for endometriosis. In the belief that antiangiogen

APA, Harvard, Vancouver, ISO, and other styles

43

Lee, Tong-Young, Stefan Muschal, Elke A. Pravda, Judah Folkman, Amir Abdollahi, and Kashi Javaherian. "Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins." Blood 114, no. 9 (2009): 1987–98. http://dx.doi.org/10.1182/blood-2008-12-197236.

Full text

Abstract:

Angiostatin, a proteolytic fragment of plasminogen, is a potent endogenous antiangiogenic agent. The molecular mechanisms governing angiostatin's antiangiogenic and antitumor effects are not well understood. Here, we report the identification of mitochondrial compartment as the ultimate target of angiostatin. After internalization of angiostatin into the cell, at least 2 proteins within the mitochondria bind this molecule: malate dehydrogenase, a member of Krebs cycle, and adenosine triphosphate synthase. In vitro and in vivo studies revealed differential regulation of key prosurvival and angi

APA, Harvard, Vancouver, ISO, and other styles

44

Vishwanatha, JamboorK, and JessicaM Castañeda-Gill. "Antiangiogenic mechanisms and factors in breast cancer treatment." Journal of Carcinogenesis 15, no. 1 (2016): 1. http://dx.doi.org/10.4103/1477-3163.176223.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Benny, Ofra, Kei Nakai, Takeru Yoshimura, et al. "Broad Spectrum Antiangiogenic Treatment for Ocular Neovascular Diseases." PLoS ONE 5, no. 9 (2010): e12515. http://dx.doi.org/10.1371/journal.pone.0012515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Malozhen, S. A., S. V. Trufanov, and D. A. Krakhmaleva. "Antiangiogenic therapy in the surgical treatment of pterygium." Vestnik oftal'mologii 136, no. 5 (2020): 177. http://dx.doi.org/10.17116/oftalma2020136052177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Adelberg, David E., and William L. Dahut. "Antiangiogenic agents in the treatment of prostate cancer." Drug Discovery Today: Therapeutic Strategies 7, no. 1-2 (2010): 9–15. http://dx.doi.org/10.1016/j.ddstr.2011.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Shavarova, E., E. Khachaturyan, I. Pokatayev, and Zh D. Kobalava. "Current diagnosis and treatment of arterial hypertension induced by antiangiogenic antitumour agents." Clinical pharmacology and therapy 37, no. 2 (2023): 32–36. http://dx.doi.org/10.32756/0869-5490-2023-2-32-36.

Full text

Abstract:

The use of angiogenesis inhibitors (anti-VGEF antibodies and tyrosine kinase inhibitors) in oncology significantly increases both the tumor response to therapy and the risk of cardiovascular toxicity. Arterial hypertension is the main adverse effect of antiangiogenic therapy frequently limiting the doses of angiogenesis inhibitors, although it is also considered as a possible surrogate marker of the effectiveness of targeted therapy. In 2022, the recommendations of the European Society of Cardiology on the prevention and correction of cardiotoxicity of antitumor therapy were published. The art

APA, Harvard, Vancouver, ISO, and other styles

49

Borisenko, T. E., and D. V. Lukyanova. "Factors influencing the outcome of antiangiogenic therapy for macular neovascularization." Modern technologies in ophtalmology 60, no. 2 (2025): 109–10. https://doi.org/10.25276/2312-4911-2025-2-109-110.

Full text

Abstract:

Background Macular neovascularization (MN) is one of the leading causes of vision loss in patients over 50 years of age. Treatment of MN with first-line antiangiogenic therapy has a significant effect. However, the therapeutic response may vary among patients. Studying local factors such as anatomical features of the eye, the state of retinal vessels, inflammation, and the level of pigmentation that can affect the effectiveness of therapy is important for optimizing treatment and increasing its effectiveness [1]. Objective To identify local factors that determine the response to first-line ant

APA, Harvard, Vancouver, ISO, and other styles

50

Quiros-Gonzalez, Isabel, Michal R. Tomaszewski, Monika A. Golinska, et al. "Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models." Cancer Research 82, no. 8 (2022): 1658–68. http://dx.doi.org/10.1158/0008-5472.can-21-0626.

Full text

Abstract:

Abstract Angiogenesis is an established prognostic factor in advanced breast cancer, yet response to antiangiogenic therapies in this disease remains highly variable. Noninvasive imaging biomarkers could help identify patients that will benefit from antiangiogenic therapy and provide an ideal tool for longitudinal monitoring, enabling dosing regimens to be altered with real-time feedback. Photoacoustic tomography (PAT) is an emerging imaging modality that provides a direct readout of tumor hemoglobin concentration and oxygenation. We hypothesized that PAT could be used in the longitudinal sett

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!